Sanjay Chanda - Net Worth and Insider Trading
Sanjay Chanda Net Worth
The estimated net worth of Sanjay Chanda is at least $285,634 dollars as of 2024-06-10. Sanjay Chanda is the SVP, Drug Development of Anacor Pharmaceuticals Inc and owns about 29,087 shares of Anacor Pharmaceuticals Inc (ANAC) stock worth over $285,634. Details can be seen in Sanjay Chanda's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Sanjay Chanda has not made any transactions after 2015-03-04 and currently still holds the listed stock(s).
Transaction Summary of Sanjay Chanda
Sanjay Chanda Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Sanjay Chanda owns 1 companies in total, including AN2 Therapeutics Inc (ANTX) .
Click here to see the complete history of Sanjay Chanda’s form 4 insider trades.
Insider Ownership Summary of Sanjay Chanda
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| ANTX | AN2 Therapeutics Inc | 2022-03-24 | Chief Development Officer |
Sanjay Chanda Latest Holdings Summary
Sanjay Chanda currently owns a total of 1 stock. Sanjay Chanda owns 29,087 shares of Anacor Pharmaceuticals Inc (ANAC) as of March 4, 2015, with a value of $285,634.
Latest Holdings of Sanjay Chanda
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| ANAC | Anacor Pharmaceuticals Inc | 2015-03-04 | 29,087 | 9.82 | 285,634 |
Holding Weightings of Sanjay Chanda
Sanjay Chanda Form 4 Trading Tracker
According to the SEC Form 4 filings, Sanjay Chanda has made a total of 0 transactions in Anacor Pharmaceuticals Inc (ANAC) over the past 5 years. The most-recent trade in Anacor Pharmaceuticals Inc is the sale of 5,000 shares on March 4, 2015, which brought Sanjay Chanda around $225,000.
Insider Trading History of Sanjay Chanda
- 1
Sanjay Chanda Trading Performance
Sanjay Chanda Ownership Network
Sanjay Chanda Owned Company Details
What does AN2 Therapeutics Inc do?
Who are the key executives at AN2 Therapeutics Inc?
Sanjay Chanda is the Chief Development Officer of AN2 Therapeutics Inc. Other key executives at AN2 Therapeutics Inc include 10 percent owner Adjuvant Global Health Technology Fund De, L.p. , Chief Strategy Officer Kevin Michael Krause , and director & Chief Executive Officer Eric Easom .
AN2 Therapeutics Inc (ANTX) Insider Trades Summary
Over the past 18 months, Sanjay Chanda made no insider transaction in AN2 Therapeutics Inc (ANTX). Other recent insider transactions involving AN2 Therapeutics Inc (ANTX) include a net sale of 223,880 shares made by Kabeer Aziz , a net sale of 223,880 shares made by Adjuvant Global Health Technology Fund De, L.p. , and a net sale of 10,000 shares made by Kevin Michael Krause .
In summary, during the past 3 months, insiders sold 0 shares of AN2 Therapeutics Inc (ANTX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 565,631 shares of AN2 Therapeutics Inc (ANTX) were sold and 1,787,778 shares were bought by its insiders, resulting in a net purchase of 1,222,147 shares.
AN2 Therapeutics Inc (ANTX)'s detailed insider trading history can be found in Insider Trading Tracker table.
AN2 Therapeutics Inc Insider Transactions
Sanjay Chanda Mailing Address
Above is the net worth, insider trading, and ownership report for Sanjay Chanda. You might contact Sanjay Chanda via mailing address: C/o Anacor Pharmaceuticals, Inc., 1020 East Meadow Circle, Palo Alto Ca 94303.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
